Table 3.
Description of the main involved drugs in aseptic meningitis
| IVIG (n = 84, 29.8%) | n | Antalgic/anaesthetic (n = 23, 8.2%) | n | SAID (n = 11, 3.9%) | n |
|---|---|---|---|---|---|
| Privigen | 31 | Paracetamol | 5 | Hydrocortisone (IT and IV) | 3 |
| Tegeline | 21 | Sufentanil | 4 | Methylprednisolone (IT) | 3 |
| Clairyg | 15 | Bupivacaine (IR and NC) | 4 | Prednisone (PO) | 3 |
| Octagam | 7 | Morphine | 2 | Betamethasone (PO) | 1 |
| Sandoglobulin | 5 | Articaine (DEN) | 1 | Prednisolone (ID) | 1 |
| Gammagard | 2 | Codeine | 1 | Sexual hormone (n = 4, 1.4%) | N |
| Kiovig | 2 | Dextropropoxyphene | 1 | Estradiol | 1 |
| Vivaglobin | 1 | Paracetamol/ascorbic acid/pheniramine | 1 | Follitropin | 1 |
| NSAID (n = 39, 13.8%) | n | Oxycodone | 1 | Oxytocin | 1 |
| Ibuprofen | 17 | Ibuprofen/pseudoephedrine | 1 | Progesterone | 1 |
| Sulfasalazine | 6 | Ropivacaine (IS) | 1 | Other antineoplastic drugs (n = 3, 1.1%) | n |
| Ketoprofen | 5 | Tramadol | 1 | Carmustine | 1 |
| Naproxen | 3 | Vaccine (n = 21, 7.4%) | n | Cisplatin | 1 |
| Tiaprofenic acid | 2 | Yellow fever vaccine | 5 | Cyclophosphamide | 1 |
| Celecoxib | 2 | DTCP vaccine | 3 | Immunosuppressive drugs (n = 2, 0.7%) | n |
| Diclofenac | 2 | Typhoid fever vaccine | 2 | Azathioprine | 1 |
| Aspirin | 1 | Influenza vaccine | 2 | Sirolimus | 1 |
| Rofecoxib | 1 | Meningococcal A C W Y vaccine | 2 | Antiemetic drugs (n = 1, 0.4%) | n |
| Antimicrobials (n = 31, 11.0%) | n | HVA vaccine | 2 | Ondansetron | 1 |
| Amoxicillin (± clavulanic acid) | 14 | Influenza vaccine | 1 | Antihistaminic drugs (n = 1, 0.4%) | n |
| Sulfamethoxazole/trimethoprim | 5 | H1N1 vaccine | 1 | Dexchlorpheniramine | 1 |
| Aciclovir | 1 | Meningococcal A B vaccine | 1 | Contrast agents (n = 1, 0.4%) | n |
| Amikacin | 1 | Meningococcal B vaccine | 1 | Iopamidol | 1 |
| Aztreonam | 1 | HVB vaccine | 1 | DMARD (n = 1, 0.4%) | n |
| Bismuth/metronidazole/tetracycline | 1 | Neuro‐ and psychotropic drugs (n = 16, 5.7%) | n | Leflunomide | 1 |
| Cefazolin | 1 | Lamotrigine | 4 | Human fibrinogen (n = 1, 0.4%) | n |
| Ceftazidime | 1 | Zolpidem | 2 | Human fibrinogen | 1 |
| Ceftriaxone | 1 | Alprazolam | 1 | Alpha 1 adrenergic drugs (n = 1, 0.4%) | n |
| Fumagillin | 1 | Amitryptiline | 1 | Phenylephrine | 1 |
| Linezolide | 1 | Carbamazepine | 1 | PPI (n = 1, 0.4%) | n |
| Norfloxacin | 1 | Citalopram | 1 | Esomeprazole | 1 |
| Tetracycline | 1 | Clozapine | 1 | Sympathomimetic drugs (n = 1, 0.4%) | n |
| Valaciclovir | 1 | Diazepam | 1 | Adrenalin | 1 |
| Monoclonal antibodies (n = 23, 8.2%) | n | Lithium | 1 | Other (n = 3, 1.1%) | n |
| Adalimumab | 5 | Lormetazepam | 1 | Allopurinol | 1 |
| Cetuximab | 4 | Tetrazepam | 1 | Mizolastine | 1 |
| Infliximab | 4 | Venlafaxine | 1 | Folic acid | 1 |
| Efalizumab | 3 | Antimetabolite (n = 14, 5.0%) | n | ||
| Rituximab | 3 | Methotrexate (IT, IV, PO, NC) | 9 | ||
| Golimumab | 1 | Cytarabine (IT and IV) | 5 | ||
| Ipilimumab | 1 | ||||
| Nivolumab | 1 | ||||
| Tocilizumab | 1 |
DEN, loco‐regional anaesthesia in dental procedures; DMARD, disease‐modifying antirheumatic drug; HVA, hepatitis virus A; HVB, hepatitis virus B; ID, intradural; IS, intraspinal; IT, intrathecal; IVIG, intravenous immunoglobulins; IV, intravenous; NSAID, nonsteroidal anti‐inflammatory; NC, not communicated; PO, per os; PPI, proton pump inhibitors; SAID, steroidal anti‐inflammatory.